Drugs in development for the treatment of chronic hepatitis B

Current Hepatitis Reports

Volumn 11, Issue 2, 2012, Pages 111-118

  Strasser, Simone I ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Bay 41 4109; Clevudine; Emtricitabine; Entecavir; GS 9620; Hepatitis B; Interferon; Myrcludex B; Nitazoxanide; Novel therapies; Prodrug; REP 9 AC; Tenofovir

Indexed keywords

2 AMINO 9 (1 PHOSPHONOMETHOXYCYCLOPROPYLMETHYL)PURINE BIS(PIVALOYLOXYMETHYL) ESTER; 9 [2 [[[[1 (ISOPROPOXYCARBONYL)ETHYL]AMINO]PHENOXYPHOSPHINYL]METHOXY]PROPYL]ADENINE; ADEFOVIR; ANTIVIRUS AGENT; BAY 41 4109; CARNITINE; CIRCULAR DNA; CLEVUDINE; CLOSED CIRCULAR DNA; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; GS 7340; GS 9620; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAGOCICLOVIR; LAMIVUDINE; MYRCLUDEX B; NITAZOXANIDE; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON LAMBDA; PRADEFOVIR; REP 9 AC; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS DNA;

ADD ON THERAPY; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARM EDEMA; ARTICLE; ASTHENIA; CARDIOVASCULAR DISEASE; CLOSTRIDIUM DIFFICILE INFECTION; COMBINATION CHEMOTHERAPY; CREATINE KINASE BLOOD LEVEL; CRYPTOSPORIDIOSIS; DELTA AGENT HEPATITIS; DRUG DOSE COMPARISON; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FATTY LIVER; GIARDIASIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFUSION RELATED REACTION; INNATE IMMUNITY; LACTATE BLOOD LEVEL; LACTATE DEHYDROGENASE BLOOD LEVEL; LEG EDEMA; LONG TERM CARE; MITOCHONDRIAL MYOPATHY; MIXED INFECTION; MONOTHERAPY; MYALGIA; NEPHROTOXICITY; NEUROPATHY; NONHUMAN; PANCREATITIS; SEROCONVERSION; SIDE EFFECT; TOXIC MYOPATHY; UNSPECIFIED SIDE EFFECT; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS INHIBITION; VIRUS MUTATION; VIRUS NUCLEOCAPSID; VIRUS REPLICATION; WEAKNESS;

EID: 84865724821     PISSN: 15403416     EISSN: 15410706     Source Type: Journal    
DOI: 10.1007/s11901-012-0131-9     Document Type: Article

References (58)

1. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661-2.
2. European Association For The Study Of The Liver. Clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227-42.
3. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263-83.
4. Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. Control of cccDNA function in hepatitis B virus infection. J Hepatol. 2009;51:581-92.
5. Snow-Lampart A, Chappell B, Curtis M, et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology. 2011;53:763-73.
6. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology. 2009;49:1151-7.
7. Thomas H, Foster G, Platis D. Mechanisms of action of interferon and nucleoside analogues. J Hepatol. 2003;39:S93-8.
8. Chang CM, Jeng KS, Hu CP, et al. Production of hepatitis B virus in vitro by transient expression of cloned HBV DNA in a hepatoma cell line. EMBO J. 1987;6:675-80.
9. Lütgehetmann M, Mancke LV, Volz T et al. Human chimeric uPA mouse model to study hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology. 2012;55:685-94.
10. Zlotnick A, Lee A, Bourne CR, Johnson JM, Domanico PL, Stray SJ. In vitro screening for molecules that affect virus capsid assembly and other protein association reactions. Nat Protoc. 2007;2:490-8.
11. Locarnini S, Zoulim F. Molecular genetics of HBV infection. Antivir Ther. 2010;15 Suppl 3:3-14.
12. Doo EC, Ghany MG. Hepatitis B virology for clinicians. Clin Liver Dis. 2010;14:397-408.
13. Bertoletti A, Maini MK, Ferrari C. The host-pathogen interaction during HBV infection: immunological controversies. Antivir Ther. 2010;15 Suppl 3:15-24.
14. Lee JS, Park ET, Kang SS, et al. Clevudine demonstrates potent antiviral activity in naive chronic hepatitis B patients. Intervirology. 2010;53:83-6.
15. Kim JH, Yim HJ, Jung ES, et al. Virologic and biochemical responses to clevudine in patients with chronic HBV infectionassociated cirrhosis: data at week 48. J Viral Hepat. 2011;18:287-93.
16. Yang HW, Lee BS, Lee TH, et al. Efficacy of initial treatment with clevudine in naive patients with chronic hepatitis B. Korean J Intern Med. 2010;25:372-6.
17. Jang JH, Kim JW, Jeong SH, et al. Clevudine for chronic hepatitis B: antiviral response, predictors of response, and development of myopathy. J Viral Hepat. 2011;18:84-90.
18. Lau GK, Leung N. Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study. Korean J Hepatol. 2010;16:315-20.
19. Yoon EL, Yim HJ, Lee HJ, Lee YS, Kim JH, Jung ES, Kim JH, Seo YS, Yeon JE, Lee HS, Um SH, Byun KS. Comparison of clevudine and entecavir for treatment naive patients with chronic hepatitis B virus infection: two-year follow-up data. J Clin Gastroenterol. 2011;45:893-9.
20. Kwon SY, Park YK, Ahn SH, et al. Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients. J Virol. 2010;84:4494-503.
21. • Seok JI, Lee DK, Lee CH, et al. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology. 2009;49:2080-6.
22. Tak WY, Park SY, Jung MK, et al. Mitochondrial myopathy caused by clevudine therapy in chronic hepatitis B patients. Hepatol Res. 2009;39:944-7.
23. Kim BK, Oh J, Kwon SY, Choe WH, Ko SY, Rhee KH, et al. Clevudine myopathy in patients with chronic hepatitis B. J Hepatol. 2009;51:829-34.
24. Kim HJ, Park DI, Park JH, et al. Comparison between clevudine and entecavir treatment for antiviral-naïve patients with chronic hepatitis B. Liver Int. 2010;30:834-40.
25. Tak WY, Park SY, Cho CM, et al. Clinical, biochemical, and pathological characteristics of clevudine-associated myopathy. J Hepatol. 2010;53:261-6.
26. Berg T, Marcellin P, Zoulim F, et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronichepatitis B virus infection. Gastroenterology. 2010;139(4):1207-17.
27. Patterson SJ, George J, Strasser SI, et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut. 2011;60:247-54.
28. Si-Ahmed SN, Pradat P, Zoutendijk R, et al. Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study. Antiviral Res. 2011;92:90-5.
29. Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. 2011;53:62-72.
30. Fung J, Lai CL, Yuen MF. LB80380: a promising new drug for the treatment of chronic hepatitis B. Expert Opin Investig Drugs. 2008;17:1581-8.
31. Min CH, Kim CR, Steffy K, Averett D, Locarnini S, Shaw T. The active metabolite of LB80380/ANA380, a novel nucleotide analog, exhibits activity in vitro against multiple clinically relevant hepatitis B virus mutants. J Hepatol. 2007;46 Suppl 1:S159.
32. Yuen MF, Kim J, Kim CR, et al. A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B. Antivir Ther. 2006;11:977-83.
33. Yuen MF, Han KH, Um SH, et al. Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease. Hepatology. 2010;51:767-76.
34. Lai CL, Ahn SH, Lee KS, et al. Week 48 analysis of a phase IIb study of the efficacy and safety of LB80380 vs. entecavir in treatment-naive patients with chronic hepatitis B. Hepatology. 2011;54 (Suppl S1):1442A.
35. Reddy KR, Matelich MC, Ugarkar BG, et al. Pradefovir: a prodrug that targets adefovir to the liver for the treatment of hepatitis B. J Med Chem. 2008;51:666-76.
36. Lee WA, He GX, Eisenberg E, et al. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother. 2005;49:1898-906.
37. Jacquard AC, Brunelle MN, Pichoud C, et al. In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2′,3′-dideoxy-3′-fluoroguanosine. Antimicrob Agents Chemother. 2006;50:955-61.
38. Michalak TI, Zhang H, Churchill ND, Larsson T, Johansson NG, Öberg B. Profound antiviral effect of oral administration of MIV-210 on chronic hepadnaviral infection in a woodchuck model of hepatitis B. Antimicrob Agents Chemother. 2009;53:3803-14.
39. Zeuzem S, Arora S, Bacon B, et al. Pegylated interferon-lambda (pegIFN-l) shows superior viral response with improved safety and tolerability versus pegIFN-α2a in HCV patients (G1/2/3/4): EMERGE phase IIb through week 12. J Hepatol. 2011;54 Suppl 1:S538-9.
40. Pagliaccetti NE, Chu EN, Bolen CR, Kleinstein SH, Robek MD. Lambda and alpha interferons inhibit hepatitis B virus replication through a common molecular mechanism but with different in vivo activities. Virology. 2010;401:197-206.
41. Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J Virol. 2005;79:3851-4.
42. Petersen J, Dandri M, Mier W, et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol. 2008;26:335-41.
43. Ben M' Barek M, Volz T, Lutgehetmannet M, et al. Administration of the entry inhibitor Myrcludex-B after establishment of hepatitis B virus infection prevents viral spreading among human hepatocytes in uPa mice. J Hepatol. 2011;54 Suppl 1:S33.
44. Deres K, Schröder CH, Paessens A, et al. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science. 2003;299:893-6.
45. Stray SJ, Bourne CR, Punna S, et al. A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly. Proc Natl Acad Sci USA. 2005;102:8138-43.
46. Stray SJ, Zlotnick A. BAY 41-4109 has multiple effects on Hepatitis B virus capsid assembly. J Mol Recognit. 2006;19:542-8.
47. Brezillon N, Brunelle M-N, Massinet H et al. Antiviral activity of Bay 41-4109 on hepatitis B virus in humanized Alb-uPA/SCID mice. PLoS One. 2011; Epub ahead of print.
48. Bernstein DI, Goyette N, Cardin R, et al. Amphipathic DNA polymers exhibit antiherpetic activity in vitro and in vivo. Antimicrob Agents Chemother. 2008;52:2727-33.
49. Cardin RD, Bravo FJ, Sewell AP, et al. Amphipathic DNA polymers exhibit antiviral activity against systemic Murine Cytomegalovirus infection. Virol J. 2009;6:214.
50. Vaillant A, Juteau JM, Lu H, et al. Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation. Antimicrob Agents Chemother. 2006;50:1393-401.
51. Matsumura T, Hu Z, Kato T, et al. Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. Gastroenterology. 2009;137:673-81.
52. Mahtab MA, Bazinet M, Vaillant A. REP 9 AC: a potent HBsAg release inhibitor that elicits durable immunological control of chronic HBV infection. Hepatology. 2011;54(Suppl S1):478A.
53. Mahtab MA, Bazinet M, Patient R, Roingeard P, Vaillant A. Nucleic acid polymers REP 9 AC/REP 9 AC' elicit sustained immunologic control of chronic HBV infection. Glob Antiviral J. 2011;7 Suppl 1:64A.
54. Isogawa M, Robek MD, Furuichi Y, Chisari FV. Toll-Like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol. 2005;79:7269-72.
55. Lanford RE, Guerra B, Chavez DC, et al. Therapeutic efficacy of the TLR7 agonist GS-9620 for HBV chronic infection in chimpanzees. J Hepatol. 2011;54 Suppl 1:S45.
56. Lopatin U, Wolfgang G, Kimberlin R, et al. A phase-I, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single escalating oral doses of GS-9620 in healthy subjects. J Hepatol. 2011;54 Suppl 1:S296.
57. Keeffe EB, Rossignol JF. Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides. World J Gastroenterol. 2009;15(15):1805-8.
58. Rossignol JF, Keeffe EB. Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C. Future Microbiol. 2008;3:539-45.